Steven J. O’Day

Learn More
Department of Medicine, Division of Translational Medicine and Human Genetics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA GlaxoSmithKline, Upper Providence, PA The Angeles Clinic and Research Institute, Los Angeles, CA The Sarah Cannon Research Institute, Nashville, TN Departments of Investigational(More)
Jyoti D. Patel, Northwestern University; Blasé Polite, University of Chicago Medicine, Chicago, IL; Lada Krilov, American Society of Clinical Oncology, Alexandria, VA; Sylvia Adams and William L. Carroll, New York University Cancer Institute; Carol Aghajanian, Mark G. Kris, and Gary K. Schwartz, Memorial Sloan-Kettering Cancer Center, New York, NY; Ethan(More)
BACKGROUND In patients with metastatic melanoma and KIT amplifications and/or mutations, therapy with imatinib mesylate may prolong survival. 18F-labeled 2-fluoro-2-deoxy-D-glucose (18F-FDG) PET/CT may be used to assess metabolic response. We investigated associations of metabolic response, mutational status, progression-free survival and overall survival(More)
Intelligent Autonomy (IA) is a multi-year program within the Office of Naval Research (ONR) Autonomous Operations (AO) Future Naval Capabilities (FNC) program. The primary goal of the effort is to develop and demonstrate technologies for highly automated and fully autonomous mission planning and dynamic re-tasking of multiple classes of Naval unmanned(More)
Stage IV metastatic melanoma patients historically have a poor prognosis with 5-10% 5-year survival. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA4), is one of the first treatments to provide beneficial durable responses in advanced melanoma. However, less than 25% of those treated benefit, treatment is expensive, and side(More)
BACKGROUND Ipilimumab (IPI), an anti-CTLA-4 antibody, and vemurafenib (VEM), a BRAF inhibitor, have distinct mechanisms of action and shared toxicities (e.g., skin, gastrointestinal [GI] and hepatobiliary disorders) that may preclude concomitant administration. Concurrent administration of IPI and VEM previously showed significant dose-limiting(More)
The role of estrogen receptor A (ERA) in melanoma is unknown. ERA expression may be regulated in melanoma via hypermethylation of promoter CpG islands. We assessed ERA hypermethylation in primary and metastatic melanomas and sera as a potential tumor progression marker. ERA methyl-ation status in tumor (n = 107) and sera (n = 109) from American Joint(More)
2647 Inhibition of Tumor Growth by a Dominant Negative Mutant of the Insulin-like Growth Factor I Receptor with a Bystander Effect. Krzysztof Reiss, Consuelo D’Ambrosio, Xiao Tu, Chi lu. and Renato Baserga. 2657 a-Cyano3-hydroxy3-methyl-N-[4-(trifluoromethoxy)phenyu Propenamide: An Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase with(More)
2268 Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer Shinichi Kageyama, Hiroaki Ikeda, Yoshihiro Miyahara, Naoko Imai, Mikiya Ishihara, Kanako Saito, Sahoko Sugino, Shugo Ueda, Takeshi Ishikawa, Satoshi Kokura, Hiroaki Naota, Kohshi Ohishi, Taizo Shiraishi, Naoki Inoue, Masashige Tanabe,(More)
  • 1